Six-month delay to post-Brexit rules dubbed unenforceable by industry

9 April 2024
brexit_uk_europe_horizon_large

Nearly eight years after the UK voted to leave the European Union (EU), the government is still delaying on introducing certain new rules that impact the life sciences industry.

Importers of laboratory reagents and materials used in the manufacture of medicines in the sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

"We are pleased the government has listened to our sector’s legitimate and reasonable concerns"The Department for Environment, Food and Rural Affairs (Defra) has agreed that intermediate animal by-products, laboratory reagents and derived products for pharmaceutical use, including the manufacture of pharmaceuticals and laboratory reagents, will be treated as low-risk until July 31, under the new post-Brexit import regime, known as the Border Target Operating Model.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical